European drug regulators have found no evidence that popular diabetes and weight-loss medications such as Ozempic and Wegovy increase the risk of suicidal thoughts or actions.
On Friday, the European Medicines Agency’s regulatory committee released the results of its review. It is the latest study to indicate that there is no known link between a new class of obesity medicines and suicide.
The European Union’s regulators initiated the assessment last July in response to anecdotal allegations that people using the medications were thinking about self-harm.
The regulators looked at studies, post-marketing data, and other research on pharmaceuticals used in almost a dozen therapies to treat disorders. The researchers did not look at tirzepatide, a medicine found in pills advertised as Mounjaro and Zepbound.
Both organizations stated that they will continue to closely monitor reports of suicidal thoughts or behaviors among patients taking GLP-1 receptor agonists. Officials advised patients taking the medications to report any mental health or other issues to their healthcare professionals.
